Vanda Pharmaceuticals challenges the FDA over delays in addressing its hearing request for tradipitant, citing agency layoffs ...

The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a ...

Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's ...

The company has also made changes to its executive compensation, adjusting annual bonuses and base salaries, and awarding restricted stock units. These developments reflect Vanda Pharmaceuticals’ ...

Vanda Pharmaceuticals (VNDA) stated that “FDA bureaucrats have committed to delay Vanda’s request for a hearing on the approvability of ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

They currently have a $20.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday ...

FMR LLC increased its holdings in Vanda Pharmaceuticals by 25.9% during the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock worth $702,000 after buying an ...

Vanda's stock remains undervalued, and I am cautious about investing due to management issues and market skepticism. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a small company with a strong ...

The latest price target for Vanda Pharmaceuticals (NASDAQ:VNDA) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $20.00 expecting VNDA to rise to ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.